Group 1 - The company aims to enhance its core competitiveness and improve decision-making efficiency through the establishment of a strategic committee [1][2] - The strategic committee is responsible for researching and proposing recommendations on the company's long-term development strategy and major investment decisions [2][10] - The strategic committee consists of three directors, including at least one independent director, and is chaired by the chairman of the board [2][4] Group 2 - The strategic committee must meet at least once a year, with provisions for temporary meetings if proposed by a majority of members [4][12] - Decisions made by the strategic committee require the presence of at least two-thirds of its members and must be approved by a majority vote [4][15] - Meeting records must be kept for ten years, detailing the date, attendees, agenda, and voting results [4][23]

江苏康为世纪生物科技股份有限公司 范围。 公司董事会秘书被解聘或辞任离任的, 应当接受董事会的离任审查, 并办理有关档案文件、具体工作的移交手续。 董事会秘书被解聘或者辞任时, 公司应当及时向上海证券交易所报 告, 说明原因并公告。 董事会秘书辞任后未完成上述报告和公告义务的, 或者未完成离任 审查、文件和工作移交手续的, 仍应承担董事会秘书的责任。 第五章 董事会秘书工作内容 第一章 总则 第四条 董事会秘书的主要职责是: 第一条 按照建立现代企业制度的要求, 为进一步完善江苏康为世纪生物科 技股份有限公司(以下简称"公司")法人治理结构, 明确董事会秘书的 权利义务和职责, 依据《中华人民共和国公司法》(以下简称"《公司 法》")、《中华人民共和国证券法》及其他有关法律、法规规定和《江 苏康为世纪生物科技股份有限公司章程》(以下简称"公司章程")制定 本工作细则。 第二条 公司设董事会秘书 1 名。董事会秘书为公司的高级管理人员, 对董事 会负责。董事会秘书是公司与公司上市的证券交易所(以下简称"证 券交易所")之间的指定联络人。公司应当指派董事会秘书和代行董 事会秘书职责的人员、证券事务代表负责与证券交 ...

（以下简称"《公司法》" ）、《上市公司治理准则》 第一条 为进一步完善江苏康为世纪生物科技股份有限公司（以下简称"公司"）的法 人治理结构，充分发挥独立董事在公司治理中的作用，根据《中华人民共和 国公司法》 《上市公司独立董 江苏康为世纪生物科技股份有限公司 独立董事行使上述第一款所列职权的，公司应当及时披露。上述职权不能正 常行使的，公司应当披露具体情况和理由。 不定期会议召开的通知应至少包括上述第（一）、（三）项内容。 第十九条 出席会议的独立董事均对会议所议事项有保密义务，不得擅自披露有关信息。 第十二条 独立董事行使以下特别职权前应经公司独立董事专门会议审议，并经全体独 立董事过半数同意： (一) 独立聘请中介机构，对公司具体事项进行审计、咨询或者核查； (二) 向董事会提议召开临时股东会； (三) 提议召开董事会会议。 第十三条 独立董事专门会议通知至少包括以下内容： (一) 会议召开时间、地点、方式； (二) 会议期限； (三) 会议需要讨论的议题； (四) 会议联系人及联系方式； (五) 会议通知的日期。 事管理办法》《上海证券交易所科创板股票上市规则》《江苏康为世纪生物科 技股份有限公司章程 ...

第一章 总则 江苏康为世纪生物科技股份有限公司 第十四条 提名委员会每年至少召开一次会议, 并于会议召开五日前通知全体委员; 经 二分之一以上委员或召集人提议可召开临时会议, 并于会议召开三日前通知 全体委员。 第十五条 提名委员会会议由召集人召集和主持, 召集人不能或者拒绝履行职责时, 应 指定一名独立董事委员代为履行职责。 第十六条 会议通知应至少包括以下内容: (一) 会议召开时间、地点、方式; (二) 会议期限; (三) 会议需要讨论的议题; (四) 会议联系人及联系方式; (五) 会议通知的日期。 第十七条 提名委员会会议应由三分之二以上的委员出席方可举行; 每一名委员有一票 表决权; 会议作出的决议, 必须经全体委员的过半数通过。 第十八条 提名委员会委员可以亲自出席会议, 也可以委托其他委员代为出席会议并行 使表决权。委托其他委员代为出席会议并行使表决权的, 应向会议主持人提交 授权委托书, 授权委托书应不迟于会议表决前提交给会议主持人。 第十九条 授权委托书应由委托人和被委托人签名, 应至少包括以下内容: (一) 委托人姓名; (二) 被委托人姓名; (三) 代理委托事项; (四) 对会议议题 ...

《上市公司章程指引》及《江苏康为 江苏康为世纪生物科技股份有限公司 世纪生物科技股份有限公司章程》（以下简称"《公司章程》"）的规 定，结合公司实际情况，制定本制度。 第一章 总则 董事提出辞任的，公司应当在 60 日内完成补选，确保董事会及其专 门委员会构成符合法律法规和公司章程的规定。 第八条 公司董事、高级管理人员为自然人，有下列情形之一的，不能担任 公司的董事或高级管理人员： 第二条 本制度适用于公司全体董事（含独立董事）及高级管理人员的辞任、 任期届满、解任以及其他导致董事、高级管理人员实际离职等情形。 第二章 离职情形与生效条件 第三条 公司董事辞任应当提交书面辞职报告。董事辞任的，自公司收到通 知之日生效，公司将在两个交易日内披露有关情况。 第四条 如存在以下情形的，在改选出的董事就任前，原董事仍应当依照法 律、行政法规、部门规章和《公司章程》规定，履行董事职务，但 存在相关法规另有规定的除外： (一) 董事任期届满未及时改选，或者董事在任期内辞任导致董事 会成员低于法定最低人数； (二) 审计委员会成员辞任导致审计委员会成员低于法定最低人数， 或者欠缺担任召集人的会计专业人士； (三) 独立董 ...

Core Points - The article outlines the regulations and responsibilities of the Audit Committee of Jiangsu Kangwei Century Biotechnology Co., Ltd, emphasizing the need for independent directors and their qualifications [2][4][5] - The Audit Committee is responsible for overseeing financial reporting, internal controls, and external audits, ensuring compliance with relevant laws and regulations [3][6][7] Group 1: Audit Committee Structure - The Audit Committee must consist of directors who are not senior management, with a majority being independent directors [2][4] - Independent directors must have relevant professional knowledge and experience to effectively supervise and evaluate audit work [2][4] - The committee is responsible for proposing the hiring or replacement of external auditors and reviewing their fees and terms [5][6] Group 2: Responsibilities and Authority - The main responsibilities of the Audit Committee include supervising external audits, evaluating internal audits, and reviewing financial information [6][7] - The committee must ensure the accuracy and completeness of financial reports and address any significant issues related to fraud or misrepresentation [6][7] - The committee has the authority to hire independent consultants and legal advisors as needed [10][12] Group 3: Meeting Procedures - The Audit Committee is required to hold at least one regular meeting each quarter and can convene additional meetings as necessary [10][12] - A quorum for meetings requires the presence of at least two-thirds of the committee members [10][12] - Meeting records must be kept for a minimum of ten years, detailing attendance, agenda, and decisions made [11][13]

Core Viewpoint - The document outlines the information disclosure regulations for Jiangsu Kangwei Century Biotechnology Co., Ltd, emphasizing the importance of timely, accurate, and complete information disclosure to protect the rights of the company and its investors [1][2][3]. Group 1: General Provisions - The company must comply with various laws and regulations, including the Company Law and Securities Law, to ensure proper information disclosure [1]. - Information disclosure is defined as the act of publicly announcing significant information that could impact stock prices, in accordance with regulatory standards [3]. - The company and its information disclosure obligors must ensure that disclosed information is truthful, accurate, complete, and easily understandable [2][4]. Group 2: Information Disclosure Obligations - The company must disclose all information that could significantly affect stock prices or investment decisions, including major events and financial performance [9][10]. - Information disclosure must be conducted fairly, ensuring all investors have equal access to information without any selective disclosure [2][4]. - The company is required to report any major events that may not meet the legal disclosure standards but could still impact stock prices [4][9]. Group 3: Reporting Procedures - The company must follow a structured process for drafting, reviewing, and disclosing periodic reports, which include quarterly, semi-annual, and annual reports [13][14]. - Major events must be disclosed immediately, detailing the cause, current status, and potential impact on the company [28]. - The board of directors is responsible for ensuring that all disclosures are accurate and timely, with specific roles assigned to the board secretary and other management personnel [22][23]. Group 4: Internal Reporting and Compliance - The company has established internal reporting mechanisms to ensure that all significant information is communicated to the board in a timely manner [39][40]. - Directors and senior management are responsible for monitoring and reporting any significant changes in the company's operations or financial status [61][62]. - The company must maintain confidentiality regarding undisclosed information and ensure that all personnel comply with these confidentiality requirements [76][77].

General Overview - The document outlines the information disclosure management system for Jiangsu Kangwei Century Biotechnology Co., Ltd, focusing on the procedures for deferring and exempting information disclosure obligations [2][3]. Information Disclosure Deferral and Exemption - The company can defer or exempt information disclosure without applying to the Shanghai Stock Exchange if the information falls under specific conditions outlined in the listing rules [3]. - Information that involves trade secrets or confidential business information can be deferred or exempted if it meets certain criteria, such as potential harm to the company or others if disclosed [3][4]. Criteria for Deferral and Exemption - The criteria for deferring or exempting disclosure include: 1. Disclosure of core technology information that may lead to unfair competition. 2. Disclosure of operational information that could infringe on the commercial secrets of the company or third parties. 3. Other situations where disclosure could severely harm the interests of the company or others [3][4]. Responsibilities and Procedures - The company must maintain strict confidentiality regarding state secrets and cannot use the excuse of confidentiality to promote business [3][4]. - A mechanism for accountability is established for any failure to report deferral or exemption matters in a timely manner, with potential penalties for responsible individuals [4][5]. Documentation and Record-Keeping - The company is required to keep detailed records of any deferral or exemption actions, including the reasons and internal review processes, for a minimum of ten years [4][5]. - Specific forms and documentation are outlined for the approval process of deferring or exempting disclosures, including a confidentiality commitment from individuals aware of the information [5][8].

Core Viewpoint - The company intends to increase the use of temporarily idle raised funds for cash management, aiming to enhance the efficiency of fund utilization and maximize shareholder returns while ensuring the safety of the raised funds and the implementation of investment projects [1][5][7]. Summary by Sections Fundraising Basic Situation - The company was approved for its initial public offering (IPO) on November 27, 2020, with a total of 48.676088 million shares issued at a price of RMB 43.22 per share, raising a total of RMB 2,103.7805 million. After deducting issuance costs, the net amount raised was RMB 1,942.3216 million [1]. Fund Investment Project Basic Situation - The total planned investment for the projects funded by the raised capital is RMB 1,355.8911 million, with the same amount allocated for fundraising [2]. Previous Use of Idle Funds for Cash Management - The company previously approved the use of up to RMB 880 million of temporarily idle funds for cash management, allowing for the purchase of safe, liquid financial products. This approval is valid for 12 months from the board's decision [2][3]. Current Increase in Cash Management Usage - The company plans to increase the cash management limit by RMB 60 million, bringing the total to RMB 940 million. This increase is also valid for 12 months from the board's approval [4][6]. Investment Purpose - The aim is to rationally utilize temporarily idle funds for cash management to improve fund efficiency and increase returns for shareholders, without affecting the implementation of investment projects [3][5]. Investment Products - The company will invest in high-safety, principal-protected, and liquid products, including but not limited to guaranteed financial products, structured deposits, large certificates of deposit, and time deposits [4]. Implementation and Disclosure - The company’s chairman is authorized to make investment decisions within the approved limits, and the finance department will organize the implementation. The company will comply with relevant disclosure obligations [4][5]. Impact on the Company - The increase in cash management usage will not affect the normal operation of the company’s funds or the implementation of investment projects, and it is expected to generate additional investment returns for the company and its shareholders [5][7]. Review Procedures and Opinions - The board and supervisory committee have approved the increase in cash management usage, confirming that it aligns with legal requirements and does not harm the interests of the company or minority shareholders [6][7].

中生北控生物科技(08247)发布截至2025年6月30日止6个月中期业绩，集团营业收入人民币9581.5万元， 同比减少28.4%;股东应占亏损1797.6万元，同比扩大36.37%;每股亏损0.124元。 ...